Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 3/2013

01-03-2013 | Original Paper

Prevalence and Predictors of Drug Use Among Adolescents with HIV Infection Acquired Perinatally or Later in Life

Authors: Latoya C. Conner, Jeffrey Wiener, Jennifer V. Lewis, Rhonda Phill, Ligia Peralta, Sulachni Chandwani, Linda J. Koenig

Published in: AIDS and Behavior | Issue 3/2013

Login to get access

Abstract

We examined the prevalence and predictors of drug use among a diverse group of adolescents living with HIV infection acquired perinatally or through sexual risk behaviors (“behaviorally acquired”). Adolescents ages 13–21 (n = 166) who were receiving care at one of five pediatric/adolescent HIV clinics in three US cities (Baltimore MD, Washington DC, and New York NY) and were enrolled in a behavioral intervention were interviewed at baseline regarding lifetime drug use experiences and depression symptoms. A majority of study participants reported using alcohol (57.2%) and marijuana (51.2%); 48.8% reported tobacco/cigarette use. The mean age of onset of use for each type of drug was 14 years or younger. A larger proportion of participants with behaviorally acquired HIV than adolescents with perinatally acquired HIV reported lifetime use of alcohol (76.1 vs. 44.4%), marijuana (73.1 vs. 36.4%), tobacco (70.2 vs. 34.3%), and club drugs (22.4 vs. 3%) (all p < 0.001).
Literature
1.
2.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. [Table 1]. Atlanta: U.S. Department of Health and Human Services; 2009.
3.
4.
Whitmore SK, Hughes DP, Taylor AW, Koenig LJ. Estimated numbers and demographic characteristics of persons living with perinatally acquired HIV disease, 34 States, United States, 2007. 2010 July. Poster presented at the 18th international AIDS conference (Vienna, Austria).
5.
Centers for Disease Control and Prevention. Youth risk behavior survey surveillance—United States, 2005. MMWR. 2005;55:14–22.
6.
Johnston LD, O’Malley PM, Bachman JG. Monitoring the future national results in adolescent drug use: overview of key findings, 2002. Rockville, MD: National Institute on Drug Abuse; 2002. NIH publication No. 06-5882.
7.
8.
Suris JC, Parera N. Sex, drugs and chronic illness: health behaviours among chronically ill youth. Eur J Public Health. 2005;15(5):484–8.PubMedCrossRef
9.
Rosenblum A, Magura S, Fong C. Substance use among young adolescents in HIV-affected families: resiliency, peer deviance, and family functioning. Subst Use Misuse. 2005;40:581–603.PubMedCrossRef
10.
Houck CD, Lescano CM, Brown LK, Tolou-Shams M, Thompson J, DiClemente R, et al. “Islands of risk”: subgroups of adolescents at risk for HIV. J Pediatr Psychol. 2006;31:619–29.PubMedCrossRef
11.
Bachanas PJ, Morris MK, Lewis-Gess JK, Sarett-Cuasay EJ, Flores AL, Sirl KS, et al. Psychological adjustment, substance use, HIV knowledge, and risky sexual behavior in at-risk minority females: developmental differences during adolescence. J Pediatr Psychol. 2002;27(4):373–84.PubMedCrossRef
12.
Taney MR, Naar-King S, Murphy DA, Parsons JT, Janisse H. Multiple risk behaviors among youth living with Human Immunodeficiency Virus in five U.S. cities. J Adolesc Health. 2010;46:11–6.CrossRef
13.
American Academy of Pediatrics Committee on Pediatric AIDS. Reducing the risk of HIV infection associated with illicit drug use. Pediatrics. 2006;117(2):566–71.CrossRef
14.
15.
Kennedy CA, Hill JM, Schleifer SJ. HIV/AIDS and substance use disorders. In: Frances RJ, Miller SI, Mack AH, editors. Clinical textbook of addictive disorders. 3rd ed. New York: The Guilford Press; 2005. p. 411–36.
16.
Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr. 2002;31(2):62–9.CrossRef
17.
Zweben JE, Denning P. The alcohol and drug wildcard: Substance use and psychiatric problems in people with HIV. San Francisco: UCSF AIDS Health Project; 1998.
18.
Chesney MA, Farmer P, Leandre F, Malow R, Starace F. Human immunodeficiency virus and acquired immunodeficiency syndrome. In: Sabate E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. p. 95–106.
19.
Ammassari A, Trotta MP, Murri R, Castelli F, Narcisco P, Noto P, et al. Correlates and predictors of adherence to highly active retroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(3):S123–7.PubMedCrossRef
20.
Comulada WS, Swendeman DT, Rotheram-Borus MJ, Mattes KM, Weiss RE. Use of HAART among young people living with HIV. Am J Health Behav. 2003;27:389–400.PubMedCrossRef
21.
Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2005;159:764–70.PubMedCrossRef
22.
Naar-King S, Templin T, Wright K, Frey M, Parsons JT, Lam P. Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care STDs. 2006;20:44–7.PubMedCrossRef
23.
Lyketsos CG, Treisman GJ. Mood disorders in HIV infection. Psychiatr Ann. 2001;31(1):45–9.
24.
Brown G. The impact of HIV/AIDS on the African American woman and child: epidemiology, cultural and psychosocial issues and nursing management. Assoc Black Nurs Faculty J. 2001;12(3):60–2.
25.
Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV—defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir Immune Defic Synd. 2006;42(3):298–306.CrossRef
26.
Colibazzi T, Hsu TT, Gilmer WS. Human immunodeficiency virus and depression in primary care: a clinical review. Prim Care Companion J Clin Psychiatr. 2006;8(4):201–11.CrossRef
27.
Pao M, Lyon M, D’Angelo LJ, Schuman WB, Tipnis T, Mrazek DA. Psychiatric diagnoses in adolescents seropositive for the human immunodeficiency virus. Arch Pediatr Adol Med. 2000;154:240–4.
28.
Marhefka SL, Lyon M, Koenig LJ, Orban L, Stein R, Lewis J, et al. Emotional and behavioral problems and mental health service utilization of youth living with HIV acquired perinatally or later in life. AIDS Care. 2009;21(11):1447–54.PubMedCrossRef
29.
Williams PL, Leister E, Chernoff M, Nachman S, Morse E, Di Poalo V, et al. Substance use and its association with psychiatric symptoms in perinatally HIV-infected and HIV-Affected adolescents. AIDS Behav. 2010;14:1072–82.PubMedCrossRef
30.
Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection. Pediatr Inf Dis J. 2006;25(5):432–7.CrossRef
31.
Perkins DO, Leserman J, Stern RA, Baum SF, Liao D, Golden RN, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatr. 1995;152:1776–81.PubMed
32.
Coleman CL, Holzemer WL, Eller LS, Corless I, Reynolds N, Nokes KM, et al. Gender differences in use of prayer as a self-care strategy for managing symptoms in African Americans living with HIV/AIDS. J Assoc Nurses AIDS Care. 2006;17(4):16–23.PubMedCrossRef
33.
Shacham E, Basta TB, Reece M. Symptoms of psychological distress among African Americans seeking HIV-related mental health care. AIDS Patient Care STDs. 2002;22(5):413–21.CrossRef
34.
Abramowtiz S, Koenig LJ, Chandwani S, Orban L, Stein R, LaGrange R, et al. Characterizing social support: global and specific social support experiences of HIV-infected youth. AIDS Patient Care STDs. 2009;23(5):323–30.CrossRef
35.
Michaelis A. Living with HIV from birth into young adulthood: key issues facing a pioneering generation of HIV-positive youth in Baltimore. Workshop presented at the 136th annual meeting and expo of the American Public Health Association, Oct 2008, San Diego.
36.
American Medical Association. Guidelines for adolescent prevention services. Chicago, IL: AMA; 1997. Product No. OP020997.
37.
Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. Pediatrics. 1999;104(1):35–42.PubMedCrossRef
38.
Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH project of the adolescent medicine HIV/AIDS research network: design, methods, and selected characteristics of participants. J Adolesc Health. 1998;22:300–11.PubMedCrossRef
39.
Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatr. 1961;4:561–71.PubMedCrossRef
40.
Roberts R, Lewisohn P, Seeley J. Screening for adolescent depression: a comparison of depression scales. J Am Acad Child Adolesc Psychiatr. 1991;30(1):58–66.CrossRef
41.
Strober M, Green J, Carlson G. Utility of the beck depression inventory with psychiatrically hospitalized adolescents. J Clin Consult Psychol. 1981;49:482–3.CrossRef
42.
Teri L. Depression in adolescence: it’s relationship to assertion and various aspects of self-esteem. J Clin Child Psychol. 1982;11:101–6.
43.
Leadbeater B, Linares O. Depressive symptoms in black and Puerto Rican adolescent mothers in the first 3 years postpartum. Dev Psychopathol. 1992;4:451–68.CrossRef
44.
Barrera M, Garrison-Jones C. Properties of the Beck depression inventory as a screening instrument for adolescent depression. J Abnorm Child Psychol. 1988;16(3):263–73.PubMedCrossRef
45.
46.
Anderson JR. Module 3: assessment issues and strategies in HOPE program training package 2006. Washington, DC: American Psychological Association; 2006:3–58.34.
47.
Vega WA, Zimmerman RS, Warheit GJ, Apospori E, Gil AG. Risk factors for early adolescent drug use in four ethnic and racial groups. Am J Public Health. 1993;83(2):185–9.PubMedCrossRef
48.
Crepaz N, Marks G. Are negative affective states associated with HIV sexual risk behaviors? A meta-analytic review. Health Psychol. 2001;20:291–9.PubMedCrossRef
49.
O’Leary A, Broadwell SD, Yao P, Hasin D. Major depression, alcohol and drug use disorders do not appear to account for the sexually transmitted disease and HIV epidemics in the Southern United States. Sex Transm Dis. 2006;33(7):S70–7.PubMed
50.
Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27–40.PubMedCrossRef
51.
52.
Marlatt G. Harm reduction: pragmatic strategies for managing high-risk behaviors. New York: The Guilford Press; 1998.
53.
Miller WR, Rollnick S. Motivational interviewing: preparing people for change. New York: The Guilford Press; 2002.
54.
Prochaska JO, DiClimente CC. Stages of change in the modification of problem behaviors. Sage: Newbury Park; 1992.
Metadata
Title
Prevalence and Predictors of Drug Use Among Adolescents with HIV Infection Acquired Perinatally or Later in Life
Authors
Latoya C. Conner
Jeffrey Wiener
Jennifer V. Lewis
Rhonda Phill
Ligia Peralta
Sulachni Chandwani
Linda J. Koenig
Publication date
01-03-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9950-x

Other articles of this Issue 3/2013

AIDS and Behavior 3/2013 Go to the issue

Original Paper

HIV Risk Behaviors Among Black/African American and Hispanic/Latina Female Partners of Men Who Have Sex With Men and Women

Original Paper

Impact of an HIV Prevention Intervention on Condom Use among Long Distance Truckers in India

Original Paper

Rates and Correlates of HIV and STI Infection Among Homeless Women

Original Paper

High Prevalence of Anal Human Papillomavirus Infection and Associated Risky Behaviors in Men Infected with Human Immunodeficiency Virus in Taiwan

Substantive Review

A Systematic Review to Quantitatively Evaluate ‘Stepping Stones’: A Participatory Community-based HIV/AIDS Prevention Intervention

Original Paper

Awareness and Acceptability of Female Condoms Among Monogamous Hong Kong Chinese Female Sexually Transmitted Infection Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits